{"id":"18f-psma","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4650355","moleculeType":"Small molecule","molecularWeight":"989.97"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"18F-PSMA targets PSMA, a transmembrane glycoprotein highly expressed on prostate cancer cells and certain other malignancies. The fluorine-18 radiolabel enables PET imaging to visualize and localize PSMA-positive lesions, facilitating tumor detection, staging, and treatment planning. This diagnostic imaging agent helps clinicians identify metastatic disease and guide therapeutic decisions.","oneSentence":"18F-PSMA is a fluorine-18 labeled radiotracer that binds to prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of PSMA-expressing tumors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:25:22.741Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"PET imaging of PSMA-positive prostate cancer"},{"name":"Detection and staging of metastatic prostate cancer"}]},"trialDetails":[{"nctId":"NCT04461509","phase":"PHASE2","title":"High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy","status":"COMPLETED","sponsor":"Alessandro D'Agnolo","startDate":"2021-04-06","conditions":"Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms","enrollment":62},{"nctId":"NCT05678322","phase":"PHASE3","title":"Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2023-01-31","conditions":"Prostate Cancer","enrollment":26},{"nctId":"NCT05616650","phase":"PHASE2","title":"Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-10-19","conditions":"Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma","enrollment":42},{"nctId":"NCT05939414","phase":"PHASE3","title":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-03-12","conditions":"Oligometastatic Prostate Cancer (OMPC)","enrollment":450},{"nctId":"NCT07011342","phase":"NA","title":"Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2025-10-01","conditions":"Prostate Cancer","enrollment":70},{"nctId":"NCT07485881","phase":"","title":"18F-PSMA PET/CT Versus CT Alone in Assessment of Prostatic Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-05-01","conditions":"Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer Recurrent","enrollment":59},{"nctId":"NCT03594760","phase":"PHASE3","title":"PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer","status":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2018-12-01","conditions":"Prostate Cancer","enrollment":1000},{"nctId":"NCT07025369","phase":"PHASE2","title":"Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-08-25","conditions":"Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8","enrollment":30},{"nctId":"NCT05160480","phase":"","title":"A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, Davis","startDate":"2024-06-07","conditions":"Prostate Cancer, Breast Cancer, Neuroendocrine Tumors","enrollment":9},{"nctId":"NCT07164027","phase":"EARLY_PHASE1","title":"Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2025-11-14","conditions":"Prostate Carcinoma","enrollment":30},{"nctId":"NCT07455903","phase":"PHASE2","title":"Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT","status":"NOT_YET_RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2026-04","conditions":"Prostate Cancer, Localized Prostate Carcinoma","enrollment":50},{"nctId":"NCT05413850","phase":"PHASE1, PHASE2","title":"Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection","status":"RECRUITING","sponsor":"Blue Earth Therapeutics Ltd","startDate":"2022-07-20","conditions":"Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC","enrollment":82},{"nctId":"NCT07285057","phase":"PHASE2","title":"Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-02-10","conditions":"Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma","enrollment":120},{"nctId":"NCT07089550","phase":"","title":"PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2025-04-02","conditions":"PSMA Positive Tumors or Tumor Tissues, Prostate Cancer Metastatic","enrollment":1300},{"nctId":"NCT03861676","phase":"EARLY_PHASE1","title":"Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-08-03","conditions":"Prostate Cancer","enrollment":20},{"nctId":"NCT06335914","phase":"NA","title":"Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-04-03","conditions":"Advanced Prostate Cancer","enrollment":30},{"nctId":"NCT03995888","phase":"PHASE1","title":"Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer","status":"COMPLETED","sponsor":"Blue Earth Diagnostics","startDate":"2019-06-11","conditions":"Prostate Cancer","enrollment":24},{"nctId":"NCT07393867","phase":"PHASE2","title":"Androgen-responsive POSLUMA-guided Intra-prostatic Boost","status":"NOT_YET_RECRUITING","sponsor":"Martin T. King, MD, PhD","startDate":"2026-03","conditions":"Intermediate Risk Prostate Cancer, High Risk Prostate Cancer, Prostate Cancer","enrollment":23},{"nctId":"NCT04573231","phase":"PHASE2","title":"Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-05-24","conditions":"Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer","enrollment":13},{"nctId":"NCT07386496","phase":"NA","title":"The Role of 18F-PSMA PET in Prostate Cancer Diagnosis in Equivocal MRI","status":"NOT_YET_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2026-03-01","conditions":"Prostate Cancer","enrollment":250},{"nctId":"NCT03535831","phase":"NA","title":"PSMA PET Registry (18F-DCFPyL)","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2018-04-27","conditions":"Carcinoma of Prostate","enrollment":142},{"nctId":"NCT06099093","phase":"PHASE4","title":"Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-04-01","conditions":"Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Carcinoma","enrollment":30},{"nctId":"NCT06145633","phase":"PHASE2","title":"Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2024-09-18","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":15},{"nctId":"NCT03173924","phase":"PHASE2","title":"18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-06-06","conditions":"Metastatic Prostate Cancer, Prostatic Neoplasms, Prostate Cancer","enrollment":96},{"nctId":"NCT03181867","phase":"PHASE2","title":"18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"National Cancer Institute (NCI)","startDate":"2017-08-03","conditions":"Prostate Neoplasms, Prostatic Cancer, Prostate Cancer","enrollment":800},{"nctId":"NCT05053152","phase":"PHASE2","title":"Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2022-04-20","conditions":"Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma","enrollment":194},{"nctId":"NCT07327515","phase":"NA","title":"PET/CT-Guided Biological Target Volume Delineation and Dose Optimization for Radioactive Seed Implantation Therapy in Malignant Tumors","status":"NOT_YET_RECRUITING","sponsor":"Li Min","startDate":"2026-01","conditions":"Malignant Tumors","enrollment":90},{"nctId":"NCT06450548","phase":"NA","title":"Dynamic 68Ga-PSMA and 18F-FDG PET/CT Analysis Prior to 177Lu-PSMA","status":"RECRUITING","sponsor":"Centre Henri Becquerel","startDate":"2025-03-05","conditions":"Prostate Cancer Metastatic","enrollment":60},{"nctId":"NCT06881823","phase":"PHASE1, PHASE2","title":"Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2026-06-29","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT07301827","phase":"NA","title":"Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-06-01","conditions":"Renal Cell Carcinoma","enrollment":66},{"nctId":"NCT03976843","phase":"PHASE2","title":"Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-12-04","conditions":"Prostate Cancer","enrollment":175},{"nctId":"NCT07084909","phase":"PHASE2, PHASE3","title":"Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC","status":"WITHDRAWN","sponsor":"Lantheus Medical Imaging","startDate":"2025-11","conditions":"Clear Cell Renal Cell Carcinoma","enrollment":""},{"nctId":"NCT06105918","phase":"PHASE1","title":"Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2023-11-29","conditions":"Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":6},{"nctId":"NCT06209567","phase":"EARLY_PHASE1","title":"A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-01-05","conditions":"High-grade Glioma, Brain Metastases, Brain Metastases, Adult","enrollment":11},{"nctId":"NCT07258056","phase":"NA","title":"GUidance In Prostate Cancer DEtection With 18F-PSMA-1007-PET/MRI and Targeted Biopsies","status":"RECRUITING","sponsor":"Mads Ryo Jochumsen","startDate":"2025-11-03","conditions":"Prostate Cancer","enrollment":100},{"nctId":"NCT06917781","phase":"NA","title":"Prostate Cancer Burden and Heterogeneity Evaluation Towards Liquid Biopsy: a Correlation Study to 18FDCFPyL PET and Patients Outcome","status":"RECRUITING","sponsor":"Institut Claudius Regaud","startDate":"2025-10-28","conditions":"Prostate Cancer","enrollment":80},{"nctId":"NCT05722925","phase":"PHASE4","title":"Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2023-10-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT05079698","phase":"PHASE1","title":"A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-10-01","conditions":"Prostate Cancer","enrollment":27},{"nctId":"NCT07220720","phase":"PHASE2","title":"POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2025-11-04","conditions":"Prostate","enrollment":30},{"nctId":"NCT06479187","phase":"PHASE4","title":"PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-06-30","conditions":"Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","enrollment":20},{"nctId":"NCT06062745","phase":"PHASE1","title":"Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-02-01","conditions":"Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma","enrollment":30},{"nctId":"NCT05919329","phase":"PHASE4","title":"Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2024-06-25","conditions":"Castration Resistant Prostate Cancer, Castration Sensitive Prostate Cancer, Prostate Adenocarcinoma","enrollment":80},{"nctId":"NCT04910425","phase":"PHASE2","title":"PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2023-06-17","conditions":"Prostate Carcinoma","enrollment":""},{"nctId":"NCT03939689","phase":"PHASE2","title":"I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).","status":"COMPLETED","sponsor":"Progenics Pharmaceuticals, Inc.","startDate":"2019-05-30","conditions":"Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Neoplasm","enrollment":120},{"nctId":"NCT04838626","phase":"PHASE2, PHASE3","title":"Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-09-07","conditions":"Prostatic Neoplasms, Prostate Cancer","enrollment":195},{"nctId":"NCT05547919","phase":"NA","title":"PSMA in Gastroenterologic Tumors (GIPSMA)","status":"RECRUITING","sponsor":"Wuerzburg University Hospital","startDate":"2022-10-01","conditions":"Gastrointestinal Cancer","enrollment":46},{"nctId":"NCT06520449","phase":"EARLY_PHASE1","title":"68Ga-NTA-476 Imaging in Prostate Cancer","status":"COMPLETED","sponsor":"Melbourne Theranostic Innovation Centre","startDate":"2024-09-13","conditions":"Prostate Cancer","enrollment":10},{"nctId":"NCT04186845","phase":"PHASE3","title":"Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence","status":"COMPLETED","sponsor":"Blue Earth Diagnostics","startDate":"2020-05-04","conditions":"Prostate Cancer","enrollment":391},{"nctId":"NCT03860987","phase":"PHASE2","title":"Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-30","conditions":"Castrate Sensitive Prostate Cancer","enrollment":12},{"nctId":"NCT04030338","phase":"","title":"Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-07-19","conditions":"Prostate Cancer, Prostate Neoplasm, Prostate Adenocarcinoma","enrollment":58},{"nctId":"NCT05009979","phase":"PHASE2","title":"18F-DCFPyL PET/CT in Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2023-01-18","conditions":"Hepatocellular Carcinoma","enrollment":8},{"nctId":"NCT06361810","phase":"PHASE1, PHASE2","title":"PSMA Therapy and Immunotherapy in Kidney Cancer","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-10-01","conditions":"Metastatic Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma","enrollment":""},{"nctId":"NCT04147494","phase":"EARLY_PHASE1","title":"Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-11-05","conditions":"Breast Carcinoma, Colon Carcinoma, Esophageal Carcinoma","enrollment":29},{"nctId":"NCT06690970","phase":"","title":"Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients","status":"RECRUITING","sponsor":"Tianjin Medical University","startDate":"2020-09-01","conditions":"PSMA-related Disease, Prostate Cancer, Positron Emission Tomography","enrollment":500},{"nctId":"NCT05155046","phase":"PHASE2","title":"18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-31","conditions":"Localized Prostate Cancer","enrollment":130},{"nctId":"NCT06059469","phase":"PHASE2","title":"PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.","status":"RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2022-05-30","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":20},{"nctId":"NCT06942104","phase":"PHASE1","title":"Imaging of Solid Tumors Using 18F-TRX","status":"RECRUITING","sponsor":"Rahul Aggarwal","startDate":"2025-07-03","conditions":"Solid Tumor, Solid Carcinoma, Castration-Resistant Prostate Carcinoma","enrollment":56},{"nctId":"NCT05095519","phase":"PHASE2","title":"Hepatocellular Carcinoma Imaging Using PSMA PET/CT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2021-09-08","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT06865768","phase":"PHASE2","title":"An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-04-18","conditions":"Prostate Carcinoma","enrollment":90},{"nctId":"NCT05534594","phase":"NA","title":"Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2022-08-19","conditions":"Medullary Thyroid Cancer, Medullary Thyroid Carcinoma, Thyroid Carcinoma, Medullary","enrollment":8},{"nctId":"NCT05712174","phase":"PHASE2","title":"A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2023-09-14","conditions":"Oncology, Prostate Cancer","enrollment":176},{"nctId":"NCT06866041","phase":"NA","title":"Biological Markers and Advanced Imaging for Prostate Cancer Progression in Active Surveillance","status":"RECRUITING","sponsor":"Università Vita-Salute San Raffaele","startDate":"2025-05-07","conditions":"Low-Risk Prostate Cancer","enrollment":74},{"nctId":"NCT06298838","phase":"","title":"High-resolution Intra-operative PSMA PET-CT in Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2025-05","conditions":"Prostate Cancer","enrollment":10},{"nctId":"NCT06935149","phase":"PHASE1","title":"Detecting Colorectal Cancer With Liver Metastatic Lesions Using Novel Precise Imaging Tools","status":"NOT_YET_RECRUITING","sponsor":"Primo Biotechnology Co., Ltd","startDate":"2025-05-01","conditions":"Liver Metastasis Colon Cancer","enrollment":5},{"nctId":"NCT05815316","phase":"PHASE2","title":"18F-PSMA PET/MRI for the Diagnosis of Clinically Significant Prostate Cancer","status":"WITHDRAWN","sponsor":"IRCCS San Raffaele","startDate":"2023-04-30","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT06919159","phase":"","title":"Intratumoral Heterogeneity on [18F]PSMA and [18F]FDG PET/CT in Predicting Invasion and Prognosis of Prostate Cancer","status":"COMPLETED","sponsor":"Jiequn Yu","startDate":"2021-07-01","conditions":"Prostate Cancer (Diagnosis), Prostate-specific Membrane Antigen, Positron Emission Tomography (PET)","enrollment":45},{"nctId":"NCT04794777","phase":"PHASE3","title":"Comparing \"Salvage\" Radiotherapy and Individualized PSMA PET/CT Targeted Treatment in With Relapsing Prostate Cancer","status":"RECRUITING","sponsor":"Stefan Carlsson","startDate":"2018-10-30","conditions":"Prostate Cancer","enrollment":450},{"nctId":"NCT04053842","phase":"PHASE2","title":"Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Glenn Bauman","startDate":"2021-02-04","conditions":"Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm","enrollment":45},{"nctId":"NCT06866782","phase":"","title":"European Registry of Next Generation Imaging in Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Fundacio Puigvert","startDate":"2024-09-17","conditions":"Prostate Cancer, Advanced Prostate Cancer, Metastatic Prostate Cancer (mPC)","enrollment":600},{"nctId":"NCT03471650","phase":"PHASE2","title":"Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-03-29","conditions":"Prostate Cancer","enrollment":150},{"nctId":"NCT06859203","phase":"","title":"A Prospective, Bicentric Evaluation of Fluciclovine PET-imaging in Patients with Prior Negative or Inconclusive PSMA-ligand PET","status":"RECRUITING","sponsor":"Technical University of Munich","startDate":"2025-03","conditions":"Biochemical Recurrence of Malignant Neoplasm of Prostate","enrollment":94},{"nctId":"NCT06460454","phase":"","title":"PROnostic Interest of 18F-FDG PET/CT in Patients With Metastatic Castration-resistant Prostate Cancer (mCPRC) Progressing","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2024-11-01","conditions":"Prostate Cancer","enrollment":100},{"nctId":"NCT06565247","phase":"PHASE3","title":"Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation","status":"RECRUITING","sponsor":"Region Västerbotten","startDate":"2024-10-14","conditions":"Prostate Cancer","enrollment":60},{"nctId":"NCT04186819","phase":"PHASE3","title":"Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.","status":"COMPLETED","sponsor":"Blue Earth Diagnostics","startDate":"2020-03-02","conditions":"Prostate Cancer","enrollment":356},{"nctId":"NCT06835426","phase":"NA","title":"High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins","status":"RECRUITING","sponsor":"Algemeen Ziekenhuis Maria Middelares","startDate":"2023-08-06","conditions":"Breast Carcinoma, Prostate Cancer Surgery, Thyroid Cancer","enrollment":150},{"nctId":"NCT06242119","phase":"","title":"Clinical Application of the J-PET Scanner Prototype","status":"RECRUITING","sponsor":"Jagiellonian University","startDate":"2024-03-07","conditions":"Prostate Cancer, Prostatic Hyperplasia, Prostatic Neoplasms","enrollment":25},{"nctId":"NCT06813898","phase":"EARLY_PHASE1","title":"An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2025-02-17","conditions":"Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":27},{"nctId":"NCT06820333","phase":"","title":"Impact of [18F] PSMA-1007 Imaging for Primary Staging of Prostate Cancer","status":"RECRUITING","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2025-01-10","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":200},{"nctId":"NCT05123300","phase":"NA","title":"PRISMA-PET - Primary Staging of Prostate Cancer With PSMA","status":"TERMINATED","sponsor":"Odense University Hospital","startDate":"2021-10-04","conditions":"Prostate Cancer","enrollment":385},{"nctId":"NCT06723665","phase":"NA","title":"The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients","status":"ENROLLING_BY_INVITATION","sponsor":"Affiliated Hospital of Jiangnan University","startDate":"2024-01-25","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT04750473","phase":"PHASE1","title":"Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-07-16","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Lobular Carcinoma, Metastatic Breast Lobular Carcinoma","enrollment":20},{"nctId":"NCT06770478","phase":"NA","title":"A Study to Evaluate the Diagnostic Efficacy of 68Ga- MY6349 PET/CT in Patients With Tumours","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2024-10-18","conditions":"Tumour of Epithelial Origin, 68Ga-MY6349","enrollment":40},{"nctId":"NCT06769893","phase":"NA","title":"A Study Evaluating the Value of 68Ga-NOTA-RCCB6 PET Imaging for Targeting CD70 in the Clinical Staging, Therapeutic Evaluation, and Restaging of Renal Cell Carcinoma, and Comparing It with 68Ga-PSMA PET/CT Imaging","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2024-06-12","conditions":"RCC, Renal Cell Cancer","enrollment":60},{"nctId":"NCT04775602","phase":"PHASE2","title":"Experimental Study to Evaluate the Impact of 18 Fluoro-PSMA (18F-PSMA) PET / CT in the Management of Patients with Prostate Cancer.","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2020-07-31","conditions":"18F-PSMA, Prostate Cancer","enrollment":550},{"nctId":"NCT06756334","phase":"EARLY_PHASE1","title":"Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in PCa Diagnosis, Recurrence, and Metastasis","status":"RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2024-12-19","conditions":"Prostate Cancer, PET/CT","enrollment":30},{"nctId":"NCT05568537","phase":"PHASE4","title":"Prostate MRI and Pylarify PSMA PET/CT","status":"WITHDRAWN","sponsor":"Corewell Health East","startDate":"2024-10","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT05761366","phase":"PHASE2","title":"Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-10-13","conditions":"Malignancy","enrollment":400},{"nctId":"NCT05709535","phase":"","title":"PSMA-PET/CT Registry","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2023-07-11","conditions":"Prostate Cancer","enrollment":128},{"nctId":"NCT06188468","phase":"NA","title":"ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Solid Tumors","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2023-10-01","conditions":"Tumor, Solid Tumor, Positron-Emission Tomography","enrollment":90},{"nctId":"NCT03232164","phase":"EARLY_PHASE1","title":"PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2017-02-02","conditions":"Prostate Cancer, Prostate Neoplasm","enrollment":126},{"nctId":"NCT05079828","phase":"NA","title":"Head-to-head Comparison of 68Ga-PSMA-11 and 18F-PSMA-1007","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2022-07-07","conditions":"Prostate Cancer","enrollment":100},{"nctId":"NCT05522257","phase":"NA","title":"PSMA Expression and PSMA PET Imaging in Soft Tissue Sarcomas and Urothelial Cell Carcinomas","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2022-08-01","conditions":"Sarcoma,Soft Tissue, Urothelial Carcinoma","enrollment":25},{"nctId":"NCT06706921","phase":"PHASE4","title":"18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"VA Greater Los Angeles Healthcare System","startDate":"2024-12-15","conditions":"Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Metastatic Prostate Cancer","enrollment":15},{"nctId":"NCT02899312","phase":"","title":"PSMA PET/CT for Assessment of Recurrent Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"British Columbia Cancer Agency","startDate":"2017-03-16","conditions":"Prostatic Neoplasms, Prostate Cancer","enrollment":2244},{"nctId":"NCT05887687","phase":"NA","title":"68Ga-P3 PET/CT Imaging in Malignancy","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2023-05-20","conditions":"Neoplasms","enrollment":350},{"nctId":"NCT04978675","phase":"PHASE1","title":"An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-08-04","conditions":"Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":29},{"nctId":"NCT06305390","phase":"","title":"Fully Hybrid 18F-PSMA PET/MRI as One-stop Approach for the Diagnosis of Clinically Significant Prostate Cancer.","status":"RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2023-12-04","conditions":"Clinical Suspicion of Prostate Cancer","enrollment":167},{"nctId":"NCT03558711","phase":"PHASE1","title":"PSMA-PET/CT for Prostate Cancer","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2018-01-04","conditions":"Prostate Cancer","enrollment":6},{"nctId":"NCT05958004","phase":"","title":"The Application Value of Prostate Specific Membrane Antigen PET/CT in Biopsy Free of PSA Grey Area Prostate Cancer","status":"COMPLETED","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2023-06-15","conditions":"Prostatic Neoplasms","enrollment":92},{"nctId":"NCT06489496","phase":"","title":"Prostate Cancer 18F-PSMA-1007 PET/CT Access Trial","status":"NOT_YET_RECRUITING","sponsor":"Alberta Health services","startDate":"2024-10-01","conditions":"Prostate Cancer","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["18F-DCFPyL Injection"],"phase":"phase_2","status":"active","brandName":"18F-PSMA","genericName":"18F-PSMA","companyName":"Alessandro D'Agnolo","companyId":"alessandro-d-agnolo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"18F-PSMA is a fluorine-18 labeled radiotracer that binds to prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of PSMA-expressing tumors. Used for PET imaging of PSMA-positive prostate cancer, Detection and staging of metastatic prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}